Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing

ROCKVILLE, Md., Sept. 12, 2017 -- (Healthcare Sales & Marketing Network) -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, a... Biopharmaceuticals, Venture Capital Synthetic Biologics, ribaxamase
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news